Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 324

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD

Open access
Lee, Thomas, Clavel, Thomas, Smirnov, Kirill, Schmidt, Annemarie, Lagkouvardos, Ilias, Walker, Alesia, Lucio, Marianna, Michalke, Bernhard, Schmitt-Kopplin, Philippe, Fedorak, Richard, Haller, Dirk·2017·Gut
DOI 10.1136/gutjnl-2015-309940
Open this paper in CoChat — free account

Abstract

Objective: Iron deficiency is a common complication in patients with IBD and oral iron therapy is suggested to exacerbate IBD symptoms. We performed an open-labelled clinical trial to compare the effects of per oral (PO) versus intravenous (IV) iron replacement therapy (IRT). Design: The study population included patients with Crohn's disease (CD; N=31), UC (N=22) and control subjects with iron deficiency (non-inflamed, NI=19). After randomisation, participants received iron sulfate (PO) or iron sucrose (IV) over 3 months. Clinical parameters, faecal bacterial communities and metabolomes were assessed before and after intervention. Results: Both PO and IV treatments ameliorated iron deficiency, but higher ferritin levels were observed with IV. Changes in disease activity were independent of iron treatment types. Faecal samples in IBD were characterised by marked interindividual differences, lower phylotype richness and proportions of Clostridiales. Metabolite analysis also showed separation of both UC and CD from control anaemic participants. Major shifts in bacterial diversity occurred in approximately half of all participants after IRT, but patients with CD were most susceptible. Despite individual-specific changes in phylotypes due to IRT, PO treatment was associated with decreased abundances of operational taxonomic units assigned to the species Faecalibacterium prausnitzii , Ruminococcus bromii , Dorea sp. and Collinsella aerofaciens . Clear IV-specific and PO-specific fingerprints were evident at the level of metabolomes, with changes affecting cholesterol-derived host substrates. Conclusions: Shifts in gut bacterial diversity and composition associated with iron treatment are pronounced in IBD participants. Despite similar clinical outcome, oral administration differentially affects bacterial phylotypes and faecal metabolites compared with IV therapy. Trial registration number: clinicaltrial.gov ( NCT01067547 ).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2015-309940

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 54

  1. 10.1371/journal.pone.0075540 · DOI
  2. 10.1016/j.crohns.2011.09.010 · DOI
  3. 10.1038/ajg.2011.232 · DOI
  4. 10.1111/j.1572-0241.2007.01744.x · DOI · Paper page
  5. 10.1007/s10534-005-4577-x · DOI · Paper page
  6. 10.1128/JB.00626-06 · DOI
  7. 10.1136/gutjnl-2014-307720 · DOI · Paper page
  8. 10.1136/gutjnl-2012-303954 · DOI · Paper page
  9. 10.1016/0140-6736(91)90663-A · DOI · Paper page
  10. 10.1136/gut.35.2.236 · DOI
  11. 10.1097/MCG.0b013e31825ca21a · DOI
  12. 10.1136/gutjnl-2013-304833 · DOI · Paper page
  13. 10.1002/ibd.20903 · DOI · Paper page
  14. 10.1186/1471-2180-11-7 · DOI · Paper page
  15. 10.1136/gut.2010.216929 · DOI · Paper page
  16. 10.1136/gutjnl-2014-308147 · DOI
  17. 10.1002/mnfr.201500125 · DOI
  18. Goldberg, 2013, Iron deficiency anemia in patients with inflammatory bowel disease, Clin Exp Gastroenterol, 6, 61, 10.2147/CEG.S43493 · DOI
  19. 10.1097/MOG.0b013e32835bdc2e · DOI
  20. 10.1111/j.1365-2036.2006.03146.x · DOI · Paper page
  21. 10.1021/pr800772b · DOI
  22. 10.1016/j.chom.2014.02.005 · DOI · Paper page
  23. 10.1053/j.gastro.2011.04.011 · DOI · Paper page
  24. 10.1371/journal.pone.0016952 · DOI
  25. 10.1111/j.1365-2036.2008.03860.x · DOI
  26. 10.1099/ijs.0.026989-0 · DOI · Paper page
  27. 10.1371/journal.pone.0090981 · DOI
  28. Bauer, 1976, Oral administration of radioactive sulfate to measure extracellular fluid space in man, J Appl Physiol, 40, 648, 10.1152/jappl.1976.40.4.648 · DOI
  29. 10.1002/jps.2600700330 · DOI
  30. 10.1136/gut.32.7.766 · DOI
  31. Beerens, 1977, Sulfate-reducing anaerobic bacteria in human feces, Am J Clin Nutr, 30, 1770, 10.1093/ajcn/30.11.1770 · DOI
  32. 10.1016/j.jpeds.2013.01.024 · DOI
  33. 10.1186/s12866-014-0334-z · DOI
  34. 10.1371/journal.pone.0058204 · DOI
  35. 10.1007/s11306-014-0677-3 · DOI
  36. 10.1016/j.ab.2009.06.036 · DOI
  37. 10.1371/journal.pone.0006386 · DOI · Paper page
  38. 10.1021/pr2003598 · DOI · Paper page
  39. 10.1021/pr060470d · DOI · Paper page
  40. 10.1111/j.1572-0241.2003.07160.x · DOI
  41. 10.3945/jn.111.153056 · DOI
  42. Heimerl, 2006, Alterations in intestinal fatty acid metabolism in inflammatory bowel disease, Biochim Biophys Acta, 1762, 341, 10.1016/j.bbadis.2005.12.006 · DOI
  43. 10.1016/j.clnu.2012.03.002 · DOI
  44. Müller, 2005, Detection of conjugated dienoic fatty acids in human vascular smooth muscle cells treated with conjugated linoleic acid, Biochim Biophys Acta, 1737, 145, 10.1016/j.bbalip.2005.09.011 · DOI
  45. 10.1186/1476-511X-9-15 · DOI
  46. Uko, 2012, Liver disorders in inflammatory bowel disease, Gastroenterol Res Pract, 2012, 642923, 10.1155/2012/642923 · DOI
  47. 10.1016/j.jneuroim.2005.05.002 · DOI · Paper page
  48. 10.1002/ibd.20527 · DOI
  49. 10.1136/gutjnl-2012-302578 · DOI · Paper page
  50. 10.1016/S0261-5614(97)80003-9 · DOI
  51. 10.1016/j.yexcr.2014.11.013 · DOI
  52. Espín, 2013, Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far, Evid Based Complement Alternat Med, 2013, 270418, 10.1155/2013/270418 · DOI · Paper page
  53. 10.1099/ijs.0.055095-0 · DOI
  54. 10.1021/jf5024615 · DOI · Paper page

Cited by

See all 324

Metadata

Authors
Lee, T., Clavel, T., Smirnov, K., Schmidt, A., Lagkouvardos, I., Walker, A., Lucio, M., Michalke, B., Schmitt-Kopplin, P., Fedorak, R., & Haller, D.
Venue
Gut
Publisher
BMJ
Published
2016-02-04
Volume
66
Issue
5
Pages
863-871
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
DOI
10.1136/gutjnl-2015-309940
OpenAlex
W2253470142
Cited by
324
References
10
FWCI
14.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. https://app.cochat.ai/papers/10.1136/gutjnl-2015-309940
The paper
Lee, T., Clavel, T., Smirnov, K., Schmidt, A., Lagkouvardos, I., Walker, A., Lucio, M., Michalke, B., Schmitt-Kopplin, P., Fedorak, R., & Haller, D. (2017). Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. https://doi.org/10.1136/gutjnl-2015-309940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.